CHP
MRNA icon

Cable Hill Partners’s Moderna MRNA Stock Holding History

Cable Hill Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,112
Closed -$208K – 245
2024
Q3 		$208K Buy
3,112
+131
+4% +$12K 0.02% 228
2024
Q2 		$354K Buy
+2,981
New +$377K 0.04% 122
2023
Q4 		– Sell
-2,490
Closed -$257K – 182
2023
Q3 		$257K Sell
2,490
-230
-8% -$25.7K 0.03% 147
2023
Q2 		$330K Sell
2,720
-149
-5% -$19.9K 0.04% 119
2023
Q1 		$441K Sell
2,869
-237
-8% -$39.1K 0.07% 85
2022
Q4 		$558K Buy
3,106
+70
+2% +$11.4K 0.1% 64
2022
Q3 		$359K Buy
3,036
+125
+4% +$19K 0.07% 90
2022
Q2 		$416K Buy
2,911
+492
+20% +$70.3K 0.1% 82
2022
Q1 		$417K Buy
2,419
+215
+10% +$36.2K 0.27% 58
2021
Q4 		$560K Sell
2,204
-2
-0.1% -$585 0.12% 67
2021
Q3 		$849K Sell
2,206
-200
-8% -$73.8K 0.2% 43
2021
Q2 		$565K Sell
2,406
-216
-8% -$38.6K 0.13% 55
2021
Q1 		$343K Buy
2,622
+296
+13% +$42.9K 0.09% 79
2020
Q4 		$243K Buy
+2,326
New +$235K 0.07% 95

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Cable Hill Partners's MRNA Position: Q4 2024 in Review

Cable Hill Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 3,112 shares — an estimated $208K sold.

Cable Hill Partners first reported a position in MRNA in Q4 2020 and held it in 14 quarters. The position peaked at $849K in Q3 2021. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Cable Hill Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Cable Hill Partners sold 3,112 Moderna shares in Q4 2024, an estimated $208K.
  • Cable Hill Partners first reported a position in Moderna in Q4 2020 and held it in 14 quarters.
  • Cable Hill Partners's Moderna position peaked at $849K in Q3 2021.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Cable Hill Partners's 13F filing for Q4 2024, filed 5 Feb 2025.